Table 2.

Biodistribution of anti-ICAM/α-Gal nanocarriers vs α-Gal in mice

	Brain		Heart		Kidney		Liver		Lung		Spleen
	α-Gal NCs	α-Gal	α-Gal NCs	α-Gal	α-Gal NCs	α-Gal	α-Gal NCs	α-Gal	α-Gal NCs	α-Gal	α-Gal NCs	α-Gal
%ID	0.13±0.01	0.25±0.01	0.33±0.04a	0.49±0.06	1.89±0.14b	10.12±0.77	18.41±1.22b	6.68±0.56	36.24±3.47b	0.74±0.07	3.11±0.43b	0.40±0.03
%ID/g	0.28±0.02b	0.56±0.03	2.12±0.32a	3.23±0.30	4.58±0.32b	24.58±1.49	12.36±0.71b	4.48±0.40	175.34±21.41b	3.80±0.33	25.69±2.78b	3.66±0.27
LR	0.11±0.02b	0.03±0.002	0.82±0.17b	0.16±0.01	1.71±0.12	1.21±0.06	4.76±0.51b	0.22±0.01	70.07±12.02b	0.19±0.02	9.32±1.48b	0.18±0.01
SI	3.67		5.13		1.41		21.64		368.79		51.78

%ID = percentage of injected dose, %ID/g = % ID per gram of tissue, LR = localization ratio, ratio of %ID/g of tissue to %ID/g of blood, SI = specificity index, calculated as the ratio of LR in an organ for the NC formulation vs the non-targeted enzyme. Organs were collected 30 min after injection. Data are mean±SEM, n≥8 mice.

^ais p<0.05,

^bis p<0.001, by Student’s t-test.